Innovent's bispecific antibody, IBI363, enters a global phase 3 trial for IO-resistant lung cancer, the first of its kind, ...

Over 150 oncologists choose their preference for combination regimens in metastatic ccRCC based on current data in the ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A study compares second-look laparoscopy and circulating tumor DNA (ctDNA) to detect residual ovarian cancer and predict ...

This is the AGAVE-201 trial [NCT04710576]. It was a phase 2 randomized trial, and they looked at 3 different dosing schedules ...

Shifting from a tumor-centric to a patient-centric approach is key for older cancer patients, focusing on functional capacity ...